PRFX
NASDAQPRF Technologies Ltd.
Price$1.38-0.06 (-4.17%)
02:15 PM07:45 PM
News · 26 weeks41-43%
2025-12-212026-06-14
Mix2390d
- SEC Filings9(39%)
- Insider7(30%)
- Other6(26%)
- M&A1(4%)
Latest news
25 items- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- PRPRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy MarketsTEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today provided an update on the advancement of DeepSolar Predict™, the Company's AI-driven renewable energy revenue optimization platform, as PRF continues to prepare the solution for planned commercial launch. DeepSolar Predict is designed to help renewable energy operators move from production monitoring and standalone forecasting to real-time revenue optimization by combining AI forecasting, storage intelligence and market-driven decision support in a single platform. DeepSolar Predict is being developed with the goal of helping renewable asset owners, operators, and energy
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- PRPRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical StudyTEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study. PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. Th
- SECSEC Form EFFECT filed by PRF Technologies Ltd.EFFECT - PRF Technologies Ltd. (0001801834) (Filer)
- SECSEC Form 424B3 filed by PRF Technologies Ltd.424B3 - PRF Technologies Ltd. (0001801834) (Filer)
- SECSEC Form F-1 filed by PRF Technologies Ltd.F-1 - PRF Technologies Ltd. (0001801834) (Filer)
- SECSEC Form SCHEDULE 13G filed by PRF Technologies Ltd.SCHEDULE 13G - PRF Technologies Ltd. (0001801834) (Subject)
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- PRPRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical TrialTEL AVIV, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug ("IND") application for OcuRing™-K, enabling the initiation of a Phase II clinical trial in patients undergoing cataract surgery. The IND clearance marks an important regulatory milestone for PRF and advances the Company's strategy to develop OcuRing™-K as a drop-less, sustai
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- PRPRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsLayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today provided a business update for the year ended December 31, 2025, in conjunction with the filing of its Annual Report on Form 20-F. 2025 and early 2026 Highlights Completed the strategic acquisition of DeepSolar, expanding PRF into AI-driven solar analytics and establishing a second high-growth operating platform.Completed a majority investment in LayerBio, adding OcuRing™-K, a patented drop-less, susta
- SECSEC Form 20-F filed by PRF Technologies Ltd.20-F - PRF Technologies Ltd. (0001801834) (Filer)
- INSIDERSEC Form 3 filed by new insider Aviel Sigal3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Baron Ellen S3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen-Arazi Efraim3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Geller Ehud3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Broder Eyal3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lawlor Augustine3 - PRF Technologies Ltd. (0001801834) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shavit Asaf3 - PRF Technologies Ltd. (0001801834) (Issuer)
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- PRPRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial EngagementsTEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar platform across utility-scale solar portfolios. The commercial collaboration agreement is structured to support the introduction and negotiation of multiple large-scale commercial engagements for DeepSolar, each with a minimum scope of 150 megawatts (MW), representing significant potential enterprise-level deployments. Blade Ranger operates at the intersection of renewable energy development, asset optimization, and infrastr
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
- SECSEC Form 6-K filed by PRF Technologies Ltd.6-K - PRF Technologies Ltd. (0001801834) (Filer)
PRFX FAQ
6 questionsWhat does PRF Technologies Ltd. do?
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.Where does PRFX stock trade?
PRF Technologies Ltd. (PRFX) is listed on NASDAQ.What sector and industry is PRFX in?
PRF Technologies Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PRF Technologies Ltd. go public?
PRF Technologies Ltd. (PRFX) completed its IPO in 2020.What companies are similar to PRFX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PRFX side-by-side with any of them on Quantisnow.How can I track PRFX on Quantisnow?
Quantisnow aggregates PRF Technologies Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRFX to receive live email and push alerts on every new disclosure.